Table 2 Research on the application of trp metabolism in digestive system tumors
From: Tryptophan metabolism in digestive system tumors: unraveling the pathways and implications
Targeted agents | Diseases | Molecules targeted | Outcomes | Ref |
|---|---|---|---|---|
1-MT | Colorectal cancer | IDO | Inhibit cell proliferation, and tumor growth | [67] |
1-MT | Pancreatic cancer | IDO | Motivate antitumor responses, and elicit tumor inflammatory necrosis | [90] |
1-L-MT | Colorectal cancer | IDO | Inhibit cell proliferation, and tumor growth | [89] |
Sertaconazole nitrate | Colorectal cancer | IDO1 | Induce autophagy and apoptosis, and inhibit tumor growth | [92] |
INCB023843, and INCB024360 | Pancreatic cancer, and colorectal cancer | IDO | Inhibit the growth of IDO-expressing tumors | [93] |
Hydrogen sulfide | Hepatocellular carcinoma | IDO1 | Decrease microvasculature density, and enhance tumor cell apoptosis | [94] |
Carbidopa | Pancreatic cancer | AHR, IDO1 | Inhibit tumor growth | [96] |
USP14 | Colorectal cancer | IDO1 | Promote immune suppression | [98] |
Sodium tanshinone IIA sulfonate | Colorectal cancer | IDO1/TDO2 | Enhance Anti-PD1 Therapy | [99] |
RY103 | Pancreatic cancer | IDO1/TDO | Inhibit cell migration, invasion, and tumor growth | [100] |
GR127935 | Colorectal cancer | 5-HT1DR | Inhibit cell invasion, and tumor metastasis | [101] |
Sb204741 | Pancreatic cancer | HTR2B | Inhibit tumor growth | [77] |
PF06845102/EOS200809 | Colorectal cancer | TDO | Improve the efficacy of checkpoint inhibitors | [102] |
Combination of Navoximod, and Atezolizumab | Pancreatic cancer | IDO1 | Not offer convincing evidence of enhancement compared to single-agent therapy | [97] |
Combination of Abrine, and Anti-PD-1 antibody | Hepatocellular carcinoma | IDO1 | Reduce immune escape | [95] |
Combination of 1-MT, and Radiation | Colorectal cancer | IDO | Enhance radiosensitivity | [103] |
Combination of Rosmarinic acid, and IDO1-shRNA | Hepatocellular carcinoma | IDO | Inhibit tumor growth | [104] |